SpectraGenetics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

SpectraGenetics is a private, tools-and-reagents company focused on accelerating GPCR drug discovery through its proprietary Fluorogen-Activating Protein (FAP) technology. The company's core offering includes over 350 plasmids and 100 validated cell lines expressing FAP-tagged human GPCRs, enabling real-time, live-cell assays to quantify receptor internalization—a critical cellular process. Its two main assay platforms, pH-FRET and SS-FRET, provide researchers with kinetic and fixed-endpoint data to study receptor behavior. Operating in the pre-clinical research tools sector, SpectraGenetics appears to be an early-revenue company serving the pharmaceutical and academic research markets.

Genetics & GenomicsDiagnostics

Technology Platform

Proprietary Fluorogen-Activating Protein (FAP) technology enabling live-cell, high-throughput assays for quantifying GPCR internalization via pH-FRET and SS-FRET assay formats.

Opportunities

The critical role of GPCRs as drug targets and the growing need for sophisticated, kinetic cell-based assays in drug discovery present a sustained market opportunity.

The company can expand by offering multiplexed internalization panels, moving into other receptor families, and forming distribution partnerships to increase global reach.

Risk Factors

The company faces competition from larger, diversified life science reagent firms and CROs.

Its growth is tightly coupled to the niche of GPCR internalization studies, and as a small private firm, it has limited commercial scale and marketing resources.

Competitive Landscape

SpectraGenetics competes in the drug discovery tools segment against major reagent suppliers (e.g., Thermo Fisher, Revvity) and specialized CROs offering GPCR assay services. Its differentiation lies in the specificity and low-background of its FAP-based internalization assays, but it must contend with established alternative technologies like beta-arrestin recruitment assays and antibody-based internalization tests.

More companies in Diagnostics & Precision Medicine →More companies in United States →